LONDON--(BUSINESS WIRE)--Predictive biomarkers can reduce unnecessary treatment and adverse effects unlike chemotherapy and targeted therapies which may cause toxic effects. The development of drugs using predictive biomarkers is being approved for the treatment of advanced stage non-small cell lung cancer. Predictive biomarkers will continue to gain popularity as they help in the development of cost-effective therapies with improved clinical benefits. This will boost the development of non-small cell lung cancer drugs using predictive biomarkers. Furthermore, this industry research report also presents a competitive analysis of the market by product (biologics, small molecule targeted therapy, and chemotherapy) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global non-small cell lung cancer drugs market is highly competitive with major vendors such as AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc., competing based on price, quality, and product/service offerings.
“North America will account for the largest non-small cell lung cancer drugs market share during the forecast period. Several factors such as the high prevalence of non-small cell lung cancer, strong pipeline, and new drug approvals are expected to drive the market in North America,” says a senior analyst at Technavio
Top five non-small cell lung cancer drugs market vendors
AstraZeneca operates through the biopharmaceuticals segment The company’s key offerings include: TAGRISSO, IRESSA, and IMFINZI.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates in this market through its biopharmaceuticals segment. The company’s key offerings include: OPDIVO and PARAPLATIN.
Eli Lilly and Company
Eli Lilly and Company runs its operations through two segments: human pharmaceutical products and animal health products. The company’s key offerings include: ALIMTA, CYRAMZA, and PORTRAZZA.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd runs its operations through two segments: pharmaceuticals and diagnostics. The company’s key offerings include: TECENTRIQ, Tarceva, Avastin, and ALECENSA.
Merck & Co., Inc.
Merck & Co., Inc. runs its operations through four segments: pharmaceutical, animal health, healthcare services, and alliances. The company’s key offering is KEYTRUDA, which is used to treat advanced non-small cell lung cancer, advanced melanoma, and other types of cancer.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Pruritus Drugs Market 2019-2023 - The market research study identifies Allergan Plc, Astellas Pharma Inc., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi, as the leading players in the global pruritus drugs market.
- Global Uveitis Drugs Market 2019-2023 - The market research study identifies AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc., as the leading players in the global uveitis drugs market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.